Back

Docosahexaenoic acid acts as QT-shortening agent with genotype-specific beneficial effects in transgenic LQT1, LQT2, LQT5 and LQT2-5 rabbit models

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Best Posters 1 - Best Posters in ventricular arrythmias and SCD Drug Treatment of Ventricular Arrhythmias ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Alessandro Castiglione

Malmo (Sweden)

4 More presentations in this session

Presentation thumbnail
Discussant : Best Posters in ventricular arrhythmias and SCD
Presentation thumbnail
SMART-MI risk-stratification algorithm: a prospective validation study
Professor K. Rizas (Munich, DE)
Abstract Slides
Presentation thumbnail
The role of magnetic resonance in patients with premature ventricular contractions and normal findings at echocardiography
Doctor R. Scorza (Stockholm, SE)
Abstract
Presentation thumbnail
Appropriate shocks and mortality in diabetic vs. non-diabetic patients with prophylactic implantable cardioverter-defibrillator
Professor H. Huikuri (Oulu, FI)
Abstract

Access the full session

Session thumbnail
Best Posters 1 - Best Posters in ventricular arrythmias and SCD

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?
thumbnail
Congress Presentation
Ventricular tachycardias

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources